InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: hwpbnj post# 45

Wednesday, 03/13/2019 10:51:54 PM

Wednesday, March 13, 2019 10:51:54 PM

Post# of 255
That's all biotechs. Dilution is the selling of common shares which means the float gets a little bit bigger. It doesn't mean your shares get reduced. So if you buy say 3,000 shares, you still have 3,000 shares after the dilution. The thing is that it adds additional shares into the float. Which if it gets too high makes it harder to go up based on market cap.

IMO with the many catalysts coming up this year and pending all positive the stock will be trading north of $10 per share.

You have first dosing of GM1 patient

Dosing of cohort 2 for PHASE 2 SUNRISE-PD study

2 more readouts for GM2 study

2 more readouts for GM1 study

2 more readouts for SUNRISE-PD study

initiation of OPMD phase 1/2 study

all throughout 2019. There are plenty of catalysts to lift the stock higher throughout the year. Of course, that's pending the data turns out strong.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.